BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC

Prostate Cancer Metastatic Clinical Trial

Official title:

Baseline Testosterone as a Prognostic and/or Predictive Biomarker in Metastatic Hormone Sensitive Prostate Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05530395
• Other study ID #: BATEMARK-YAUPCa-21
• Status: Not yet recruiting
• Start date: January 1, 2023
• Est. completion date: January 1, 2026

Study information

• Verified date: September 2022
• Source: University Hospital Virgen de las Nieves
• Contact: Ignacio Puche Sanz
• Phone: 0034 958 023 158
• Email: naho.puchesanz[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Despite large amounts of basic-science data supporting a role for androgens in PCa pathogenesis, there are conflicting clinical data on the role of endogenous testosterone in human de novo PCa pathogenesis. The investigators hypothesize that lower baseline serum testosterone is significantly associated with worse clinical outcomes in mHSPC patients undergoing continuous medical castration

Description:

Biological rationale: The 'androgen hypothesis' asserts that prostate cancer (PCa) development and progression is driven by androgens. There is significant evidence that androgens promote prostate cancer in experimental models. However, there is no clear evidence that elevations in endogenous testosterone levels promote the development of prostate cancer in humans. Indeed, despite large amounts of basic-science data supporting a role for androgens in PCa pathogenesis, there are conflicting clinical data on the role of endogenous testosterone in human PCa pathogenesis de novo. In reviewing the literature involving PCa development in PCa naive patients, there are studies implicating elevated testosterone, studies implicating lower testosterone, and studies with no association of testosterone and PCa risk. A recent review in 2015 delved into the controversial role of androgens and prostate cancer and explains the different theories about the ambiguous action of testosterone on the prostate. In 2012, a research proposed the nonlinear U-shaped behaviour or time dependency theory, which postulates that the endocrine biology of the prostate tissue depends on exposure time at a given androgen concentration, which "relies on the fluctuation of the levels of circulating sex steroids during the lifespan of the individual". Another model is the saturation model based on the observations that prostate tissue is extremely sensitive to changes in serum testosterone at low concentrations. This model suggests that there is a nonprotective effect of low testosterone against PCa but tissue becomes indifferent to changes when increasing androgen concentration reach a limit (saturation point), beyond which no further androgen-driven changes are observed. Anyway, the lack of a satisfying model to explain the relationship between androgens and PCa is simply the consequence of insufficient knowledge of the real intrinsic physiopathology of this disease. Clinical rationale: Approximately 15% of mHSPC patients primarily fail to respond to ADT. A recent consensus statement on circulating biomarkers for advanced prostate cancer highlighted the urgent need for prospective trials to clinically qualify circulating biomarkers, the greatest need being metastatic PCa. On the other hand, a very recent paper analysed baseline testosterone in hormone-naïve advanced PCa patients undergoing continuous medical castration and selected from 2 large Phase III RCTs. It demonstrated that lower baseline serum testosterone was significantly associated with worse survival end-points and warrants further prospective research in this scenario. In this era of complex and expensive next-generation markers, this simple, cheap, and well-known biomarker may still have something to say in PCa.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: January 1, 2026
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 89 Years

Eligibility

Inclusion Criteria:

• Metastatic hormone sensitive prostate cancer (mHSPC) patients diagnosed by any imaging

test (at least CT and bone scan) including:

• Any newly diagnosed mHSPC with no prior treatments.
• Primarily treated PCa that have progressed to mHSPC with no prior ADT in the last 2 years.
• Patients receiving ADT + EBRT as primary treatment will also be included.
• Patients who agree to be followed prospectively according to routine clinical practice in the context of this study.

Exclusion Criteria:

• Any prior androgen deprivation therapy (ADT) scheme 2 years before recruitment. - Any prior testosterone replacement therapy scheme 2 years before recruitment.
• Previous intermittent ADT schemes.
• Prior testicular excision surgery.
• Absence or testicular atrophy from any cause.
• Whenever further prospective clinical follow-up is not possible or patient do not accept follow-up in the context of this study.

Related Conditions & MeSH terms

• Prostate Cancer Metastatic
• Prostatic Neoplasms

Intervention

Diagnostic Test:
• Testosterone levels
Blood sample to determine testosterone levels

Locations

Country	Name	City	State
Spain	Hospital Universitario Reina Sofía	Córdoba	Andalucía
Spain	Hospital Universitario Virgen de las Nieves	Granada	Andalucía
Spain	Hospital Universitario Virgen del Rocio	Seville

Sponsors (13)

Lead Sponsor

Collaborator

Ignacio Puche Sanz

Azienda Ospedaliera San Giovanni Battista, Chinese University of Hong Kong, Hospital Neurotraumatologico de Jaen, Hospital San Carlos, Madrid, Hospital Universitario Reina Sofia de Cordoba, Hospital Universitario Torrecárdenas, Hospitales Universitarios Virgen del Rocío, Institut Mutualiste Montsouris, Medical University Innsbruck, San Raffaele University Hospital, Italy, UMC Utrecht, University of Padova

Country where clinical trial is conducted

Spain, 

References & Publications (4)

Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015 Dec;7(6):378-87. doi: 10.1177/1756287215597633. Review. — View Citation

Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, Carter HB. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2010 Mar;105(6):824-9. doi: 10.1111/j.1464-410X.2009.08853.x. Epub 2009 Sep 14. — View Citation

Rajek NJ. Developing an evening clinical experience for baccalaureate community health nursing students. J Nurs Educ. 1987 May;26(5):197-200. — View Citation

Yano M, Imamoto T, Suzuki H, Fukasawa S, Kojima S, Komiya A, Naya Y, Ichikawa T. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol. 2007 Feb;51(2):375-80. Epub 2006 Sep 12. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Early treatment failure	Proportion of patients with PSA progression or death from PCa within 12 months after initiation of treatment.	1 year
Primary	PSA response	Lowest PSA (nadir) reached after initiation of treatment	6 months
Secondary	Testosterone response.	%percent of decrease in testosterone levels at the moment of PSA nadir.	6 months
Secondary	Biochemical progression-free survival (bPFS)	PSA progression: 2 consecutive increase at least 50% or 5 ng/mL or more above PSA nadir on 2 consecutive measurements at least 2 weeks apart.	1 year
Secondary	Radiologic progression-free survival (rPFS)	Assessed by PCWG3 progression criteria on nodal, visceral and bone disease.	1 year
Secondary	Time to CRPC	Time (months) from treatment initiation to the development of a CRPC status.	1 year